A groundbreaking study presented at a major medical conference reveals that PET brain imaging can identify which Alzheimer's patients are most likely to benefit from new drug treatments, offering a path toward more personalized medicine. Researchers analyzed 124 patients and found that those showing Alzheimer's-specific brain metabolism patterns improved cognitively after one year of anti-amyloid therapy, while patients with different brain patterns experienced decline.

Why Do Some Alzheimer's Patients Respond to Treatment While Others Don't?

The FDA has recently approved two new anti-amyloid therapies that target amyloid plaques, the sticky protein clumps that accumulate in Alzheimer's brains. However, these drugs don't work equally well for everyone. Some patients improve significantly, while others show little benefit or even decline. The reason? Many people diagnosed with Alzheimer's actually have other neurological conditions contributing to their cognitive problems.

"Many patients who meet the clinical diagnosis criteria for Alzheimer's disease may have other neurological conditions contributing to cognitive impairment," explained Dr. Amanda Rose Nguyen from the David Geffen School of Medicine at UCLA.

Dr. Amanda Rose Nguyen, David Geffen School of Medicine at UCLA

This diagnostic confusion explains why treatment outcomes vary so widely. A patient might have Lewy body disease, frontotemporal lobar degeneration, or another condition that mimics Alzheimer's symptoms. Treating them with anti-amyloid drugs won't help because their underlying problem isn't amyloid accumulation.

How Can Brain Imaging Help Match Patients to the Right Treatment?

The study, which won the prestigious Henry N. Wagner, Jr. Abstract of the Year award at the Society of Nuclear Medicine and Molecular Imaging annual meeting, used a specific type of PET scan called 18F-FDG imaging. This scan measures how efficiently different brain regions use glucose, revealing distinct metabolic signatures for different types of dementia.

Researchers compared brain imaging data, treatment decisions, and cognitive test scores from patients before and after one year of anti-amyloid therapy. The results were striking: patients whose brain scans showed Alzheimer's-specific metabolism patterns demonstrated improved cognitive performance, while those with non-Alzheimer's patterns experienced significant cognitive decline.

The study identified distinct brain metabolism patterns for several conditions:

• Alzheimer's disease: Patients with this pattern showed improved cognitive scores after treatment
• Lewy body disease: A condition involving abnormal protein deposits that causes movement and cognitive problems
• Limbic-predominant Age-related TDP-43 Encephalopathy (LATE): A recently recognized dementia type affecting memory and thinking
• Frontotemporal lobar degeneration: A condition that primarily affects personality, behavior, and language

"This work demonstrates that 18F-FDG PET is an important tool in the diagnosis of dementia. Physicians can use this data to provide more personalized care, prescribing therapy to those most likely to benefit," noted Dr. Nguyen.

Dr. Amanda Rose Nguyen, David Geffen School of Medicine at UCLA

What Does This Mean for Alzheimer's Treatment Going Forward?

The implications are significant. Instead of prescribing anti-amyloid drugs to everyone who shows memory loss, doctors could use PET imaging to confirm that amyloid is actually the problem. This approach could spare patients from unnecessary medications while directing those most likely to benefit toward treatment.

Dr. Nguyen anticipates that expanded analyses later in the year will enhance the predictive power of brain metabolism patterns even further. For now, she advises clinicians to use comprehensive neuroimaging to guide individualized treatment decisions.

Meanwhile, other institutions are expanding their capacity to conduct cutting-edge Alzheimer's trials. The University of Washington's Memory and Brain Wellness Center was recently selected as one of 32 sites in the Alzheimer's Clinical Trials Consortium, a nationally funded infrastructure designed to accelerate testing of new therapies. The center will soon launch an Anti-Tau Platform Trial testing combined anti-amyloid and anti-tau therapies, representing the next frontier in personalized dementia treatment.

How to Support Brain Health Before Symptoms Appear

While personalized imaging and drug treatments represent important advances, experts emphasize that lifestyle choices made decades before symptoms appear can significantly influence dementia risk. Research increasingly shows that Alzheimer's disease is heavily influenced by modifiable lifestyle factors.

• Physical activity: Exercise is now considered one of the most powerful tools for protecting long-term brain health. It improves cognitive reserve (the brain's ability to tolerate stress and aging), stimulates growth of new neurons in the hippocampus (the memory center), increases release of brain-derived neurotrophic factor (BDNF, often called "fertilizer for the brain"), reduces inflammation associated with neurodegenerative disease, and improves blood flow and oxygen delivery to the brain
• Resistance training: Individuals with greater leg strength and muscle power consistently show larger brain volume and better-preserved cognitive function later in life. Even small movement breaks throughout the day, such as 10 air squats every hour, can improve circulation, glucose regulation, muscle activation, and neurological stimulation
• Quality sleep: Research suggests that even one night of poor sleep may increase amyloid-beta accumulation, a hallmark protein associated with Alzheimer's disease. Chronic sleep deprivation, stress, poor diet, and inactivity can contribute to loss of neuron connections, shrinking gray matter volume, reduced processing speed, memory decline, and mild cognitive impairment
• Cognitive engagement: Mentally and physically challenging activities help build neurological reserve, including reading, handwriting, meaningful conversation, and consistent movement throughout the day

The key insight is that neurological changes associated with cognitive decline can begin as early as a person's 30s, decades before memory loss appears in the 60s or 70s. This means that preventive lifestyle choices made in midlife and earlier may have profound effects on brain health in later years.

As research advances on both the diagnostic and preventive fronts, the message is clear: personalized medicine powered by brain imaging can help treat Alzheimer's more effectively, while consistent lifestyle choices can help prevent it from developing in the first place.